Aktienanalyse zu OS Therapies Inc (OSTX)OSTXOS Therapies Inc

OS Therapies Incorporated is a clinical-stage oncology company focused on the identification, development, and commercialization of new class immunotherapy candidates for solid tumors, beginning with osteosarcoma and other solid tumors. Its pipeline includes two drug technologies: OST-HER2 and OST-tADC. Its lead asset, OST-HER2, is an off-the-shelf immunotherapy, which is a type of cancer treatment that helps one’s immune system fight cancer, comprised of a genetically weakened and modified strain of Listeria monocytogenes, a species of bacteria that causes the infection listeriosis, that expresses HER2 peptides. OST-tADC is a tunable ADC with a plug-and-play platform that features tunable pH-sensitive silicone linkers (SiLinkers). Its clinical-stage cancer immunotherapy programs also include OST-AXAL for human papilloma virus (HPV)-associated cancers; OST-503 for non-small cell lung cancer (NSCLC) & glioblastoma; and OST-PSA for prostate cancer. It operates in the Healthcare sector.

OS Therapies Inc (OSTX) is a good buy right now due to its recent price of $1.64, which is significantly below the average analyst price target of $13, indicating substantial upside potential. Additionally, the stock has shown a positive 5-day change of +3.14% and a year-to-date increase of +22.39%, suggesting a recovery trend. However, the main risk is the company's ongoing financial losses, with a net income of -$10.4 million in Q1 2026, which raises concerns about its profitability and cash flow management.